Preliminary results of a phase I study: A chimeric monoclonal anti IL-6 antibody CNTO 328 in combination with docetaxel in patients with hormone refractory prostate cancer

G. R. Hudes,D. Nanus,Ming Qi,U. Prabhakar,R Corringham,Qun Jiao,Mario A. Eisenberger

Preliminary results of a phase I study: A chimeric monoclonal anti IL-6 antibody CNTO 328 in combination with docetaxel in patients with hormone refractory prostate cancer

2007

G. R. Hudes
D. Nanus
Ming Qi
U. Prabhakar
R Corringham
Qun Jiao
Mario A. Eisenberger

15521 Background: High serum levels of pro-inflammatory cytokine IL-6 may impact the progression and survival of metastatic hormone refractory prostate cancer (HRPC). CNTO328, an anti IL-6 monoclon...

Keywords:

Cancer research
Docetaxel
Monoclonal
Hormone refractory prostate cancer
Anti-IL-6
Medicine
Antibody
Pathology
phase i study
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations